转导(生物物理学)
遗传增强
细胞培养
病毒载体
造血
病毒学
生物
效价
小鼠白血病病毒
转染
病毒
干细胞
基因
细胞生物学
遗传学
重组DNA
生物化学
作者
Karim Ghani,Xiuyan Wang,Pedro O. de Campos‐Lima,Malgorzata Olszewska,Amine Kamen,Isabelle Rivière,Manuel Caruso
出处
期刊:Human Gene Therapy
[Mary Ann Liebert, Inc.]
日期:2009-05-19
卷期号:20 (9): 966-974
被引量:66
摘要
Retroviral vectors derived from the Moloney murine leukemia virus have been used in successful and promising gene therapy clinical trials. However, platforms for their large-scale production must be further developed. As a proof of principle, we reported the generation of a packaging cell line that produces amphotropic retroviral vectors in suspension and serum-free medium (SFM). In the present study, we have constructed and characterized two retroviral packaging cell lines designed for gene transfer in hematopoietic cells. These cell lines grow in suspension and SFM, and produce high-titer RD114- and gibbon ape leukemia virus (GALV)-pseudotyped vectors for a 3-month culture period. Viral particles released are as robust during repeated freeze-thaw cycles and on thermal inactivation at 37 degrees C as their counterparts produced in cells cultured adherently with serum. We also show that RD114- and GALV-pseudotyped vectors produced in suspension and SFM efficiently transduce human lymphocytes and hematopoietic stem cells. As these retroviral packaging cell lines distinctively maintain high vector titers while growing in suspension and SFM, we conclude that these cell lines are uniquely suitable for large-scale clinical-grade vector production for late-phase clinical trials involving gene transfer into hematopoietic cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI